Andrew Croner


Andrew is Counsel at Wilkinson Walsh. He has significant experience in product liability, mass tort, securities, and other complex civil and corporate litigation matters. His representative matters include serving as a member of three trial teams that successfully defended Pfizer in litigation regarding the hormone therapy medication Prempro and against allegations that Pfizer failed to warn of the risk of developing breast cancer. Andrew was also a member of the defense team that successfully obtained dismissals on behalf of Citigroup in multiple derivative and securities fraud actions arising out of the 2008 financial crisis.

Before joining the firm, Andrew practiced as an associate in the Washington, D.C. office of Paul, Weiss, Rifkind, Wharton & Garrison LLP and the Baltimore office of Goodell, DeVries, Leech & Dann LLP. While in law school, Andrew served as an Articles Editor for the George Washington Law Review.


  • Undergraduate: Johns Hopkins University, B.A. with honors
  • Law: George Washington University Law School, J.D. with honors

Notable Matters

  • Lead associate on trial team in United States v. Babich, in which Wilkinson Walsh defended a former pharmaceutical executive charged with participating in a criminal RICO conspiracy through a nine-week, nationally-reported jury trial that included testimony from more than forty witnesses.
  • Lead associate on Wilkinson Walsh team that helped secure favorable resolutions in Lovett v. Pfizer and Jackson v. Pfizer, two multi-plaintiff product liability lawsuits in Missouri state court alleging that Pfizer’s cholesterol medication, Lipitor, had caused plaintiffs to develop Type 2 diabetes.
  • Lead associate on Wilkinson Walsh team that secured a dismissal for the NFL in In re NFL Sunday Ticket Antitrust Litigation, an antitrust class action challenging the League’s distribution of television rights.
  • Member of trial teams that successfully defended Pfizer in Foust v. Wyeth, Buxton v. Wyeth, and Kammerer v. Wyeth, three product liability jury trials in which plaintiffs alleged that the company’s hormone replacement medication, Prempro, had caused them to develop breast cancer.


  • Note: A Snake in the Grass: The Constitutionality of Applying Section 798 of the Espionage Act to the Press, 77 Geo. Wash. L. Rev. 766–98 (2009).
  • Administrative Law Essay: Morrison, Edmond, and the Power of Appointments, 77 Geo. Wash. L. Rev. 1002–14 (2009).

Recent News